Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Necitumumab
Drug: Nab-Paclitaxel
Drug: Carboplatin

First Posted Date: 2015-03-19

Last Posted Date: 2020-11-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT02392507

Locations: 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Ixekizumab

First Posted Date: 2015-03-13

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT02387801

Locations: 🇺🇸
Mount Sinai School of Medicine Dermatology Clinical Trials, New York, New York, United States

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Abemaciclib

First Posted Date: 2015-03-13

Last Posted Date: 2019-03-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT02387814

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center (OCRC), Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami (CPMI), Miami, Florida, United States

and more 1 locations

A Study of LY2409021 Formulations in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY2409021

First Posted Date: 2015-03-11

Last Posted Date: 2018-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT02385084

Locations: 🇺🇸
Covance CRU, Inc, Daytona Beach, Florida, United States

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasm

Interventions: Biological: Olaratumab
Drug: Doxorubicin

First Posted Date: 2015-03-04

Last Posted Date: 2021-02-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 25

Registration Number: NCT02377752

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Suita-shi, Japan

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY2801653

First Posted Date: 2015-02-25

Last Posted Date: 2015-06-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 23

Registration Number: NCT02370485

Locations: 🇺🇸
Covance, Daytona Beach, Florida, United States

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Evacetrapib
Drug: Omeprazole

First Posted Date: 2015-02-19

Last Posted Date: 2018-10-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT02365558

Locations: 🇺🇸
Covance Madison, Madison, Wisconsin, United States

A Study of LY3154207 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: LY3154207
Drug: Placebo
Drug: Itraconazole

First Posted Date: 2015-02-19

Last Posted Date: 2015-06-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT02365571

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Ramucirumab
Drug: Capecitabine
Drug: Cisplatin
Drug: S-1
Drug: Oxaliplatin

First Posted Date: 2015-02-09

Last Posted Date: 2018-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT02359058

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Ehime, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Osaka, Japan

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Ixekizumab 80 mg Q2W
Drug: Ixekizumab 80 mg Q4W

First Posted Date: 2015-01-28

Last Posted Date: 2020-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 363

Registration Number: NCT02349295

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸
Office: Dr Robin K Dore, Tustin, California, United States
🇺🇸
Rheumatology Associates of South Florida, Boca Raton, Florida, United States

and more 102 locations

Home Terms & Conditions Privacy Policy